189 related articles for article (PubMed ID: 22492981)
1. Multidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinoma.
Gillet JP; Calcagno AM; Varma S; Davidson B; Bunkholt Elstrand M; Ganapathi R; Kamat AA; Sood AK; Ambudkar SV; Seiden MV; Rueda BR; Gottesman MM
Clin Cancer Res; 2012 Jun; 18(11):3197-206. PubMed ID: 22492981
[TBL] [Abstract][Full Text] [Related]
2. Bioinformatic profiling identifies a platinum-resistant-related risk signature for ovarian cancer.
Wu C; He L; Wei Q; Li Q; Jiang L; Zhao L; Wang C; Li J; Wei M
Cancer Med; 2020 Feb; 9(3):1242-1253. PubMed ID: 31856408
[TBL] [Abstract][Full Text] [Related]
3. A Novel Scoring System for Pivotal Autophagy-Related Genes Predicts Outcomes after Chemotherapy in Advanced Ovarian Cancer Patients.
Niu Y; Sun W; Chen K; Fu Z; Chen Y; Zhu J; Chen H; Shi Y; Zhang H; Wang L; Shen HM; Xia D; Wu Y
Cancer Epidemiol Biomarkers Prev; 2019 Dec; 28(12):2106-2114. PubMed ID: 31533939
[TBL] [Abstract][Full Text] [Related]
4. Clinical relevance of multidrug resistance gene expression in ovarian serous carcinoma effusions.
Gillet JP; Wang J; Calcagno AM; Green LJ; Varma S; Bunkholt Elstrand M; Trope CG; Ambudkar SV; Davidson B; Gottesman MM
Mol Pharm; 2011 Dec; 8(6):2080-8. PubMed ID: 21761824
[TBL] [Abstract][Full Text] [Related]
5. Unique gene expression profile based on pathologic response in epithelial ovarian cancer.
Spentzos D; Levine DA; Kolia S; Otu H; Boyd J; Libermann TA; Cannistra SA
J Clin Oncol; 2005 Nov; 23(31):7911-8. PubMed ID: 16204010
[TBL] [Abstract][Full Text] [Related]
6. Tumor genomic, transcriptomic, and immune profiling characterizes differential response to first-line platinum chemotherapy in high grade serous ovarian cancer.
Weberpals JI; Pugh TJ; Marco-Casanova P; Goss GD; Andrews Wright N; Rath P; Torchia J; Fortuna A; Jones GN; Roudier MP; Bernard L; Lo B; Torti D; Leon A; Marsh K; Hodgson D; Duciaume M; Howat WJ; Lukashchuk N; Lazic SE; Whelan D; Sekhon HS
Cancer Med; 2021 May; 10(9):3045-3058. PubMed ID: 33811746
[TBL] [Abstract][Full Text] [Related]
7. Predicting Response to Standard First-line Treatment in High-grade Serous Ovarian Carcinoma by Angiogenesis-related Genes.
Mendiola M; Redondo A; Heredia-Soto V; Herranz J; Berjón A; Hernández A; Miguel-Martín M; Crespo R; Barriuso J; Cruz P; Yébenes L; Peláez-García A; Castelo B; DE Molina AR; Feliu J; Hardisson D
Anticancer Res; 2018 Sep; 38(9):5393-5400. PubMed ID: 30194194
[TBL] [Abstract][Full Text] [Related]
8. Comparisons of the survival time of patients with ovarian cancer adopting post-operative chemotherapy by use of paclitaxel combined with carboplatin or nedaplatin.
Gao H; Yuan L; Han Y
World J Surg Oncol; 2016 Jun; 14(1):168. PubMed ID: 27341795
[TBL] [Abstract][Full Text] [Related]
9. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
10. Lung resistance-related protein (LRP) expression in malignant ascitic cells as a prognostic marker for advanced ovarian serous carcinoma.
Kerr EH; Frederick PJ; Egger ME; Stockard CR; Sellers J; DellaManna D; Oelschlager DK; Amm HM; Eltoum IE; Straughn JM; Buchsbaum DJ; Grizzle WE; McNally LR
Ann Surg Oncol; 2013 Sep; 20(9):3059-65. PubMed ID: 23525731
[TBL] [Abstract][Full Text] [Related]
11. Expression of TGFß1 and its receptors is associated with biological features of ovarian cancer and sensitivity to paclitaxel/carboplatin.
Komiyama S; Kurahashi T; Ishikawa M; Tanaka K; Komiyama M; Mikami M; Udagawa Y
Oncol Rep; 2011 Apr; 25(4):1131-8. PubMed ID: 21249319
[TBL] [Abstract][Full Text] [Related]
12. Potential predictive markers of chemotherapy resistance in stage III ovarian serous carcinomas.
Osterberg L; Levan K; Partheen K; Delle U; Olsson B; Sundfeldt K; Horvath G
BMC Cancer; 2009 Oct; 9():368. PubMed ID: 19835627
[TBL] [Abstract][Full Text] [Related]
13. Cox-LASSO Analysis Reveals a Ten-lncRNA Signature to Predict Outcomes in Patients with High-Grade Serous Ovarian Cancer.
Xu L; Wu Y; Che X; Zhao J; Wang F; Wang P; Qu X; Liu Y; Li Z
DNA Cell Biol; 2019 Dec; 38(12):1519-1528. PubMed ID: 31657627
[TBL] [Abstract][Full Text] [Related]
14. Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer.
Furlong F; Fitzpatrick P; O'Toole S; Phelan S; McGrogan B; Maguire A; O'Grady A; Gallagher M; Prencipe M; McGoldrick A; McGettigan P; Brennan D; Sheils O; Martin C; W Kay E; O'Leary J; McCann A
J Pathol; 2012 Apr; 226(5):746-55. PubMed ID: 22069160
[TBL] [Abstract][Full Text] [Related]
15. Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy.
Hartmann LC; Lu KH; Linette GP; Cliby WA; Kalli KR; Gershenson D; Bast RC; Stec J; Iartchouk N; Smith DI; Ross JS; Hoersch S; Shridhar V; Lillie J; Kaufmann SH; Clark EA; Damokosh AI
Clin Cancer Res; 2005 Mar; 11(6):2149-55. PubMed ID: 15788660
[TBL] [Abstract][Full Text] [Related]
16. Adenosine triphosphate-based chemotherapy response assay predicts long-term survival of primary epithelial ovarian cancer.
Li LY; Kim SW; Nam EJ; Lee J; Kim S; Kim YT
Int J Gynecol Cancer; 2019 Feb; 29(2):334-340. PubMed ID: 30718314
[TBL] [Abstract][Full Text] [Related]
17. Interferon regulatory factor 1 is an independent predictor of platinum resistance and survival in high-grade serous ovarian carcinoma.
Cohen S; Mosig R; Moshier E; Pereira E; Rahaman J; Prasad-Hayes M; Halpert R; Billaud JN; Dottino P; Martignetti JA
Gynecol Oncol; 2014 Sep; 134(3):591-8. PubMed ID: 24995581
[TBL] [Abstract][Full Text] [Related]
18. Keratin 5 overexpression is associated with serous ovarian cancer recurrence and chemotherapy resistance.
Ricciardelli C; Lokman NA; Pyragius CE; Ween MP; Macpherson AM; Ruszkiewicz A; Hoffmann P; Oehler MK
Oncotarget; 2017 Mar; 8(11):17819-17832. PubMed ID: 28147318
[TBL] [Abstract][Full Text] [Related]
19. FXYD5 (Dysadherin) upregulation predicts shorter survival and reveals platinum resistance in high-grade serous ovarian cancer patients.
Tassi RA; Gambino A; Ardighieri L; Bignotti E; Todeschini P; Romani C; Zanotti L; Bugatti M; Borella F; Katsaros D; Tognon G; Sartori E; Odicino F; Romualdi C; Ravaggi A
Br J Cancer; 2019 Oct; 121(7):584-592. PubMed ID: 31434988
[TBL] [Abstract][Full Text] [Related]
20. Oestrogen receptor 1 mRNA is a prognostic factor in ovarian cancer patients treated with neo-adjuvant chemotherapy: determination by array and kinetic PCR in fresh tissue biopsies.
Zamagni C; Wirtz RM; De Iaco P; Rosati M; Veltrup E; Rosati F; Capizzi E; Cacciari N; Alboni C; Bernardi A; Massari F; Quercia S; D'Errico Grigioni A; Dietel M; Sehouli J; Denkert C; Martoni AA
Endocr Relat Cancer; 2009 Dec; 16(4):1241-9. PubMed ID: 19749010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
